Clinical Trial Detail

NCT ID NCT03418324
Title Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Cedars-Sinai Medical Center
Indications

prostate cancer

Therapies

Abiraterone + Carotuximab

Carotuximab + Enzalutamide

Age Groups: adult senior

No variant requirements are available.